Contact Us
- Solutions
- Resources
- About
- Contact Us
close
Optional callout banner for highlighted news or events
Learn MoreDrug-device combination products (DDCPs) unite pharmaceutical formulation and medical device design, yet many teams develop them in siloes. This fragmented approach delays the identification of drug–device incompatibilities, risking late-stage rework and jeopardizing investor confidence.
An integrated development model reframes the process, treating drug and device as one coordinated program rather than two isolated tracks.
This guide is for pharmaceutical leaders driving DDCP programs, equipping them to avoid early development pitfalls, reduce costs and complexity, and strengthen regulatory positioning.
